Results 111 to 120 of about 757 (186)

Risks of pelvic inflammatory disease and bacterial vaginosis in adenomyosis patients using levonorgestrel intrauterine device or oral norethindrone. [PDF]

Front Endocrinol (Lausanne)
Niu SY, Yi YC, Shih YH, Tseng JJ.
europepmc   +1 more source

Hysteroscopic suture fixation for levonorgestrel-releasing intrauterine system in adenomyosis feasibility and therapeutic outcomes. [PDF]

Sci Rep
Chen C, Liu Z, Liang Z, Zhang P, Dong Y.
europepmc   +1 more source

Uterine transverse diameter and risk of LNG-IUS malposition in adenomyosis patients: a threshold effect analysis from a retrospective cohort study. [PDF]

BMC Womens Health
Lin Y, Jiang J, Lin H, Yan H, Deng T.
europepmc   +1 more source

Central Pathology Review of Endometrial Hyperplasia and Adenocarcinoma Before and After Treatment With the Levonorgestrel Intrauterine Device-Results From the feMMe Phase 2 Randomized Clinical Trial. [PDF]

Am J Surg Pathol
Baxter E, Robledo KP, Cummings M, Alizart M, Smith D, Obermair A.   +5 more
europepmc   +1 more source

Medical treatment of fibroids: FIGO best practice guidance. [PDF]

Int J Gynaecol Obstet
Diaz I, Lumsden MA, Zeppernick M.
europepmc   +1 more source

Clinical value of hysteroscopic levonorgestrel intrauterine system suture fixation in treating adenomyosis. [PDF]

BMC Womens Health
Wang J, Gong L, Xin Y, Yuan L, Li G.
europepmc   +1 more source

Suture Fixation of Levonorgestrel-Releasing Device Using the Hysteroscopic Surgery System. [PDF]

JSLS
Lai Z, Dong J, Zhang Y, Wu J.
europepmc   +1 more source

Hormonal Contraceptives and Migraine Frequency and Severity in Women: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Alju SK, Alqahtani A, Alharbi N, Munawir Farhan Alharbi R, Alsadoun F, Mutlaq Ossman Alharbi M, Sameh Abdullah Almutairi A, Lafi Musaad Alharbi A, Hamoud M Albishri B, Ahmed Habab Alrshidi K, Abdulaziz Kulaib Aljuhani S, Alhamdan N.   +11 more
europepmc   +1 more source

Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study.

Health Technol Assess, 2023
Kai J, Dutton B, Vinogradova Y, Hilken N, Gupta J, Daniels J.   +5 more
europepmc   +1 more source

Treatment Utilization after Uterine Fibroid Diagnosis by Race and Ethnicity. [PDF]

J Womens Health (Larchmt)
Mitro SD, Dyer W, Wang L, Lee C, Hedderson MM, Zaritsky E.   +5 more
europepmc   +1 more source